<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01698450</url>
  </required_header>
  <id_info>
    <org_study_id>EK: 2012-0027</org_study_id>
    <nct_id>NCT01698450</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance (MR) Guided Functional Ultrasound-Neurosurgery for Movement Disorders</brief_title>
  <official_title>MR-Guided Functional Ultrasound-Neurosurgery for Movement Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Children's Hospital, Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Children's Hospital, Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to asses the efficacy and the clinical safety of the transcranial&#xD;
      magnetic resonance guided high intensity focused ultrasound system ExAblate 4000, InSightec&#xD;
      Ltd. for functional neurosurgery in the treatment of movement disorders. The treatments to be&#xD;
      conducted in this study are non-invasive, i.e. without opening the skull, and will create&#xD;
      microthalamotomies in specific target areas such as thalamus, subthalamus and pallidum. The&#xD;
      data obtained in this study will be used to evaluate the basic safety aspects of this new&#xD;
      treatment technology and will serve as a basis for the clinical introduction of MR-guided&#xD;
      ultrasound neurosurgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lesion Size</measure>
    <time_frame>3 months</time_frame>
    <description>Size of lesion in the target area for each sonication as a function of applied energy/temperature.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Safety</measure>
    <time_frame>3 months</time_frame>
    <description>Number of Patients with Adverse Events as a Measure of Safety and Tolerability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy and QOL</measure>
    <time_frame>3 months</time_frame>
    <description>Efficacy and QOL will be quantified on respective rating scales (specified in protocol).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Essential Tremor</condition>
  <condition>Dystonia</condition>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Focused Ultrasound for Movement Disorders</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-invasive intervention with focused ultrasound (ExAblate 4000)</intervention_name>
    <description>Non-invasive brain intervention using MR-guided focused ultrasound</description>
    <arm_group_label>Focused Ultrasound for Movement Disorders</arm_group_label>
    <other_name>ExAblate 4000</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women, between 18 and 80 years, inclusive.&#xD;
&#xD;
          -  Patients who are able and willing to give consent and able to attend all study visits.&#xD;
&#xD;
          -  A diagnosis of a MD, such as Essential Tremor (ET), Idiopathic Parkinson's diseases or&#xD;
             primary Dystonia as confirmed from clinical history and examination by a movement&#xD;
             disorder neurologist.&#xD;
&#xD;
          -  A MD refractory to adequate medical treatment, or in whom the indication for Deep&#xD;
             Brain Stimulation (DBS) would be given, but DBS cannot be performed because of medical&#xD;
             comorbidities or medical reasons, or because the patient clearly confirms by written&#xD;
             statement that he does not want to undergo DBS for personal reasons (PD: increasing&#xD;
             motor fluctuations albeit optimal medical treatment &amp; unbearable side effects of&#xD;
             medication; ET: failure of adequate tremor control with Propranolol and Primidone&#xD;
             alone and in combination; Dystonia: dystonia or pain not controlled by oral&#xD;
             medication). An adequate medication trial is defined as a therapeutic dose of each&#xD;
             medication or the development of side effects as the medication dose is titrated.&#xD;
&#xD;
          -  Either the medial thalamic nuclei or the subthalamic or pallidal areas can be target&#xD;
             by the ExAblate device. The target region must be apparent on MRI such that targeting&#xD;
             can be performed with either direct visualization or by measurement from landmarks,&#xD;
             using the &quot;Stereotactic Atlas of the Human Thalamus and Basal Ganglia&quot; by Anne Morel,&#xD;
             39 analogous to our first clinical FUS study on patients with chronic pain 33.&#xD;
&#xD;
          -  Able to communicate sensations during the ExAblate MRgFUS treatment&#xD;
&#xD;
          -  Stable doses of all medications for 30 days prior to study entry and for the duration&#xD;
             of the study.&#xD;
&#xD;
          -  Significant disability due to MD despite medical treatment (speaking, feeding other&#xD;
             than liquids, bringing liquids to mouth, hygiene, dressing, writing, working, and&#xD;
             social activities)&#xD;
&#xD;
          -  Inclusion and exclusion criteria have been agreed upon by two members of the medical&#xD;
             team.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with unstable cardiac status including:&#xD;
&#xD;
               -  Unstable angina pectoris on medication&#xD;
&#xD;
               -  Patients with documented myocardial infarction within six months of protocol&#xD;
                  entry&#xD;
&#xD;
               -  Congestive heart failure requiring medication (other than diuretic)&#xD;
&#xD;
               -  Patients on anti-arrhythmic drugs&#xD;
&#xD;
          -  Patients exhibiting any behavior(s) consistent with ethanol or substance abuse as&#xD;
             defined by the criteria outlined in the DSM-IV as manifested by one (or more) of the&#xD;
             following occurring within a 12 month period:&#xD;
&#xD;
               -  Recurrent substance use resulting in a failure to fulfill major role obligations&#xD;
                  at work, school, or home (such as repeated absences or poor work performance&#xD;
                  related to substance use; substance-related absences, suspensions, or expulsions&#xD;
                  from school; or neglect of children or household).&#xD;
&#xD;
               -  Recurrent substance use in situations in which it is physically hazardous (such&#xD;
                  as driving an automobile or operating a machine when impaired by substance use)&#xD;
&#xD;
               -  Recurrent substance-related legal problems (such as arrests for substance related&#xD;
                  disorderly conduct)&#xD;
&#xD;
               -  Continued substance use despite having persistent or recurrent social or&#xD;
                  interpersonal problems caused or exacerbated by the effects of the substance (for&#xD;
                  example, arguments with spouse about consequences of intoxication and physical&#xD;
                  fights).&#xD;
&#xD;
          -  Severe hypertension (diastolic BP &gt; 100 on medication)&#xD;
&#xD;
          -  Patients with standard contraindications for MR imaging such as non-MRI compatible&#xD;
             implanted metallic devices including cardiac pacemakers, size limitations, etc.&#xD;
&#xD;
          -  Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium) including&#xD;
             advanced kidney disease&#xD;
&#xD;
          -  Severely impaired renal function (estimated glomerular filtration rate &lt; 45ml/min/&#xD;
             1.73 m2) or receiving dialysis&#xD;
&#xD;
          -  History of abnormal bleeding and/or coagulopathy&#xD;
&#xD;
          -  Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within&#xD;
             one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage&#xD;
             (e.g. Avastin) within one month of focused ultrasound procedure&#xD;
&#xD;
          -  Active or suspected acute or chronic uncontrolled infection&#xD;
&#xD;
          -  History of intracranial hemorrhage&#xD;
&#xD;
          -  Cerebrovascular disease (multiple CVA or CVA within 6 months)&#xD;
&#xD;
          -  Individuals who are not able or willing to tolerate the required prolonged stationary&#xD;
             supine position during treatment (can be up to 4 hrs of total table time.)&#xD;
&#xD;
          -  Symptoms and signs of increased intracranial pressure (e.g. headache, nausea,&#xD;
             vomiting, lethargy, and papilledema)&#xD;
&#xD;
          -  Participation in another clinical trial in the last 30 days&#xD;
&#xD;
          -  Patients unable to communicate with the investigator and staff.&#xD;
&#xD;
          -  Presence of any other neurodegenerative disease like Parkinson-plus syndromes&#xD;
             suspected on neurological examination. These include: multisystem atrophy, progressive&#xD;
             supranuclear palsy, dementia with Lewy bodies, and Alzheimer's disease.&#xD;
&#xD;
          -  Presence of significant cognitive impairment as determined with a score â‰¤ 24 on the&#xD;
             Mini Mental Status Examination (MMSE)&#xD;
&#xD;
          -  Compromised Immune System, including HIV positive serum status&#xD;
&#xD;
          -  Known life-threatening systemic disease&#xD;
&#xD;
          -  Patients with a history of seizures within the past year&#xD;
&#xD;
          -  Patients with current or a prior history of any psychiatric illness will be excluded.&#xD;
             Any presence or history of psychosis will be excluded. Patients with a significant&#xD;
             mood disorders including depression will be excluded. For the purpose of this study,&#xD;
             we consider a significant mood disorder to include any patient who has:&#xD;
&#xD;
               -  been under the care of a psychiatrist for over 3 months&#xD;
&#xD;
               -  taken antidepressant medications for greater than 6 months&#xD;
&#xD;
               -  has participated in cognitive-behavioral therapy&#xD;
&#xD;
               -  been hospitalized for the treatment of a psychiatric illness&#xD;
&#xD;
               -  received transcranial magnetic stimulation&#xD;
&#xD;
               -  received electroconvulsive therapy&#xD;
&#xD;
          -  Patients with risk factors for intraoperative or postoperative bleeding (platelet&#xD;
             count less than 100,000 per cubic millimeter, PT &gt; 14, PTT &gt; 36 or INR &gt; 1.3) or a&#xD;
             documented coagulopathy&#xD;
&#xD;
          -  Patients with brain tumors&#xD;
&#xD;
          -  Any illness that in the investigator's opinion preclude participation in this study.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernst - Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Children's Hospital, Zurich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald - Bauer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurosurgey, Kantonsspital St. Gallen, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MR-Center, University Children's Hospital</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>July 2, 2012</study_first_submitted>
  <study_first_submitted_qc>September 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2012</study_first_posted>
  <last_update_submitted>October 8, 2014</last_update_submitted>
  <last_update_submitted_qc>October 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FUS</keyword>
  <keyword>focused ultrasound</keyword>
  <keyword>functional brain disorder</keyword>
  <keyword>neuropathic pain</keyword>
  <keyword>movement disorders</keyword>
  <keyword>malignant brain tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
    <mesh_term>Movement Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

